Table 3 Multivariate logistic regression of the COVID-19 infection durations and PACS.

From: New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors

Response

AOR (95% CI)

p value

PTSD

Control

Reference

Reference

Less than 6 months

2.72 (0.93–8.11)

0.075

6–12 months

4.02 (1.33–12.15)

0.014*

More than 12 months

5.17 (1.91–14.00)

0.001*

Anxiety

Control

Reference

Reference

Less than 6 months

1.85 (0.73–4.73)

0.197

6–12 months

4.41 (1.66–11.64)

0.002*

More than 12 months

2.19 (1.04–4.63)

0.040*

Depression

Control

Reference

Reference

Less than 6 months

2.87 (1.11–7.41)

0.029*

6–12 months

5.65 (1.90–16.87)

0.002*

More than 12 months

4.43 (1.94–10.15)

0.000*

Cognitive deficit

Control

Reference

Reference

Less than 6 months

3.43 (1.30–9.00)

0.012*

6–12 months

5.25 (1.88–14.70

0.002*

More than 12 months

2.92 (1.37–6.25)

0.006*

Tics

Control

Reference

Reference

Less than 6 months

5.35 (1.59–17.75)

0.006*

6–12 months

8.43 (2.42–29.32)

0.001*

More than 12 months

3.41 (1.20–9.72)

0.022*

Response

B (95% CI)

p value

Quality of Life (EQ-5D-5L Assessment)

Control

Reference

Reference

Less than 6 months

1.21 (− 0.01 to 2.73)

0.051

6–12 months

2.09 (0.67–3.70)

0.004*

More than 12 months

1.72 (0.64–3.09)

0.002*

General Health Status (EQ-VAS)

Control

Reference

Reference

Less than 6 months

− 7.24 (− 13.99 to − 0.50)

0.036*

6–12 months

− 4.81 (− 10.93 to 1.35)

0.125

More than 12 months

− 11.28 (− 16.53 to − 6.02)

0.000*

MMRC Scale

Control

Reference

Reference

Less than 6 months

0.17 (− 0.22 to 0.55)

0.389

6–12 months

0.22 (− 0.16 to 0.60)

0.250

More than 12 months

0.11 (− 0.28 to 0.43)

0.646

BCSS

Control

Reference

Reference

Less than 6 months

1.02 (0.32–1.71)

0.004*

6–12 months

0.59 (− 0.076 to 1.26)

0.082

More than 12 months

0.26 (− 0.28 to 0.80)

0.346

  1. This table shows the comparison between the COVID-19 infection durations of COVID-19 patients and the controls to assess the prevalence of PACS symptoms among COVID-19 survivors.
  2. *P value < 0.05.
  3. PTSD Posttraumatic stress disorder, VAS Visual Analogue Scale, EQ-5D-5L EuroQol 5-dimension 5-level assessment, MMRC Modified Medical Research Council scale, BCSS Breathlessness, Cough, and Sputum Scale.